JABBOUR HENRY N
No ORCID on file
· 14 papers in corpus
· active 2006-2007
Frequent coauthors
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2007
Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2alpha, having its effect on the FP receptor. Typic…
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.
2006
A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.